Forehead Scars Following Mohs Micrographic Surgery and Reconstruction for Skin Cancer
A Prospective, Multi-Center, Double-Blind, Randomized, Placebo-Controlled Study to Evaluate the Efficacy of AbobotulinumtoxinA (BTX-A) in Improving Forehead Wounds After Mohs Micrographic Surgery and Reconstruction for Skin Cancer
Sponsor: University Hospitals Cleveland Medical Center
Terminated
Investigator left institution for private practice
Other terminated trials from University Hospitals Cleveland Medical Center
- Alopecia Areata · Phase PHASE4 · Jun 2023
- Diabetes Mellitus, Type 2 · Phase PHASE4 · Jan 2023
- Cervical Spine Surgeries · Phase NA · Feb 2022
- Abdominal Surgery · Phase NA · Mar 2021
- Safety Issues · Phase NA · May 2019
See all terminations from University Hospitals Cleveland Medical Center
Other Scar trials with similar outcome
A PHASE4 clinical study on Scar, this trial is terminated or withdrawn. The trial is conducted by University Hospitals Cleveland Medical Center and has accumulated 8 data snapshots since 2011. Longitudinal tracking of this trial contributes to a broader understanding of treatment development timelines.
Status Flow
Change History
8 versions recorded-
Sep 2024 — Present [monthly]
Terminated PHASE4
-
Jul 2024 — Sep 2024 [monthly]
Terminated PHASE4
-
Jun 2022 — Jul 2024 [monthly]
Terminated PHASE4
-
Jan 2021 — Jun 2022 [monthly]
Terminated PHASE4
-
May 2020 — Jan 2021 [monthly]
Terminated PHASE4
Status: Recruiting → Terminated
▶ Show 3 earlier versions
-
Oct 2018 — May 2020 [monthly]
Recruiting PHASE4
-
Jun 2018 — Oct 2018 [monthly]
Recruiting PHASE4
Status: Unknown Status → Recruiting
-
Jan 2017 — Jun 2018 [monthly]
Unknown Status PHASE4
First recorded
Sep 2011
Trial started
Per CT.gov start date — pre-dates our first snapshot
Eligibility Summary
No eligibility information available.
Contact Information
- University Hospitals Cleveland Medical Center
For direct contact, visit the study record on ClinicalTrials.gov .